|Mr. James A. Robinson Jr.||Pres, CEO & Director||1.07M||N/A||1970|
|Mr. Ajay Bansal||CFO & Sr. VP of Bus. Devel.||558.34k||N/A||1962|
|Dr. Cornelia Haag-Molkenteller M.D., Ph.D.||Chief Medical Officer of USI||629.79k||N/A||1959|
|Ms. Christine G. Ocampo||Chief Accounting Officer & Sr. VP||N/A||N/A||1972|
|Ryan Kubota||Exec. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Bryan E. Smith||Gen. Counsel||N/A||N/A||1979|
|Dr. David Hovland||Sr. VP of Global Regulatory Affairs||N/A||N/A||N/A|
|Mr. Kenton Stewart||Sr. VP of Market Access||N/A||N/A||N/A|
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Urovant Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.